Characterization of pseudotype VSV possessing HCV envelope proteins

Citation
Y. Matsuura et al., Characterization of pseudotype VSV possessing HCV envelope proteins, VIROLOGY, 286(2), 2001, pp. 263-275
Citations number
66
Categorie Soggetti
Microbiology
Journal title
VIROLOGY
ISSN journal
00426822 → ACNP
Volume
286
Issue
2
Year of publication
2001
Pages
263 - 275
Database
ISI
SICI code
0042-6822(20010801)286:2<263:COPVPH>2.0.ZU;2-Y
Abstract
The genome of hepatitis C virus (HCV) encodes two envelope glycoproteins (E 1 and E2), which are thought to be responsible for receptor binding and mem brane fusion resulting in virus penetration. To investigate cell surface de terminants important for HCV infection, we used a recombinant vesicular sto matitis virus (VSV) in which the glycoprotein gene was replaced with a repo rter gene encoding green fluorescent protein (GFP) and produced HCV-VSV pse udotypes possessing chimeric HCV E1 or E2 glycoproteins, either individuall y or together. The infectivity of the pseudotypes was determined by quantif ying the number of cells expressing the GFP reporter gene. Pseudotypes that contained both of the chimeric E1 and E2 proteins exhibited 10-20 times hi gher infectivity on HepG2 cells than the viruses possessing either of the g lycoproteins individually. These results indicated that both E1 and E2 enve lope proteins are required for maximal infection by HCV. The infectivity of the pseudotype virus was not neutralized by anti-VSV polyclonal antibodies , Bovine lactoferrin specifically inhibited the infection of the pseudotype virus. Treatment of HepG2 cells with Pronase, heparinase, and heparitinase but not with phospholipase C and sodium periodate reduced the infectivity. Therefore, cell surface proteins and some glycosaminoglycans play an impor tant role in binding or entry of HCV into susceptible cells, The pseudotype VSV possessing the chimeric HCV glycoproteins might offer an efficient too l for future research on cellular receptors for HCV and for the development of prophylactics and therapeutics for hepatitis C. (C) 2001 Academic Press .